These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21176237)

  • 1. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
    Clark-Langone KM; Sangli C; Krishnakumar J; Watson D
    BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
    Cronin M; Sangli C; Liu ML; Pho M; Dutta D; Nguyen A; Jeong J; Wu J; Langone KC; Watson D
    Clin Chem; 2007 Jun; 53(6):1084-91. PubMed ID: 17463177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
    Knezevic D; Goddard AD; Natraj N; Cherbavaz DB; Clark-Langone KM; Snable J; Watson D; Falzarano SM; Magi-Galluzzi C; Klein EA; Quale C
    BMC Genomics; 2013 Oct; 14():690. PubMed ID: 24103217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
    Schildgen V; Warm M; Brockmann M; Schildgen O
    Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
    Acs G; Esposito NN; Kiluk J; Loftus L; Laronga C
    Mod Pathol; 2012 Apr; 25(4):556-66. PubMed ID: 22173289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
    Hou Y; Tozbikian G; Zynger DL; Li Z
    Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
    Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
    Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
    You YN; Rustin RB; Sullivan JD
    Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance of a formalin-fixed paraffin-embedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer.
    Plamadeala V; Huang S; McCreary SM; Reitze NJ; Ewing AL; Gabrin MJ; Bennett AE; Mulligan JM; Wilson CL; Wang D
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):308-16. PubMed ID: 24717231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
    Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
    J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
    Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
    Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
    Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
    Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
    Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
    Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
    Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.